KRAS G12X

Variant type

missense mutation

Location

Chromosome 12

Exon

2

Protein change

p.G12X

cDNA change

-

Genomic coordinate

Chromosome 12

FATHMM prediction

-

Variant category

I

Variant description

The G12 mutations occur within the P-loop region of the G domain (Exon 2; Ensembl; 17579200) of KRAS, including p.G12A, p.G12C, p.G12D, p.G12R, p.G12S, p.G12V, p.G12F, and et al.. Multiple studies have now shown that patients with tumors harboring mutations in KRAS are unlikely to benefit from anti-EGFR antibody therapy, either as monotherapy (PMID: 18316791) or in combination with chemotherapy (PMID: 19114683; 21228335; 20038723; 16618717; 20921462). Moreover, KRAS mutations are negative predictors of radiographic response to the EGFR tyrosine kinase inhibitors[for review, see (PMID: 18832458; 19349489)]. Currently, there are no direct anti-KRAS therapies available.

Variant frequence

This section displays the distribution of mutated samples and tissue types (top 5).

Accoiciated drug